These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26900365)

  • 41. Corrigendum to "Contiguous pattern spreading in patients with Hodgkin's disease" [Radiother. Oncol. 47 (1998) 7-16].
    Ludwig Roth S
    Radiother Oncol; 2020 Jun; 147():99. PubMed ID: 32259752
    [No Abstract]   [Full Text] [Related]  

  • 42. Corrigendum to "Update of the systematic review of palliative radiation therapy fractionation for bone metastases" [Radiother. Oncol. 126 (2018) 547-557].
    Rich SE; Chow R; Raman S; Liang Zeng K; Lutz S; Lam H; Silva MF; Chow E
    Radiother Oncol; 2019 Jun; 135():201. PubMed ID: 30981439
    [No Abstract]   [Full Text] [Related]  

  • 43. Corrigendum to 'An Overview of Coronaviruses including the SARS-2 Coronavirus - Molecular Biology, Epidemiology and Clinical Implications' [Cur Med Res Pract. (2019) Vol. 10, pages 54-64].
    Kaul D
    Curr Med Res Pract; 2020; 10(3):135. PubMed ID: 32572377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD
    BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Corrigendum to "Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation" [Radiother Oncol 131 (2019) 127-134].
    Cubillos-Mesías M; Troost EGC; Lohaus F; Agolli L; Rehm M; Richter C; Stützer K
    Radiother Oncol; 2020 Mar; 144():231. PubMed ID: 32044167
    [No Abstract]   [Full Text] [Related]  

  • 46. Corrigendum to "Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis" [Radiother Oncol 141 (2019) 56-61].
    Chow R; Hoskin P; Schild SE; Raman S; Im J; Zhang D; Chan S; Chiu N; Chiu L; Lam H; Chow E; Lock M
    Radiother Oncol; 2020 Jul; 148():115. PubMed ID: 32361023
    [No Abstract]   [Full Text] [Related]  

  • 47. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
    Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
    J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In regards to Roach et al. defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference (Int J Radiat Oncol Biol Phys 2006;65:965-974).
    Cheung R
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1274; author reply 1274-5. PubMed ID: 17145548
    [No Abstract]   [Full Text] [Related]  

  • 49. Corrigendum to "Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging" [Radiother Oncol 113 (2014) 324-30].
    Velazquez ER; Hoebers F; Aerts HJWL; Rietbergen MM; Brakenhoff RH; Leemans RC; Speel EJ; Straetmans J; Kremer B; Lambin P
    Radiother Oncol; 2017 Aug; 124(2):337-338. PubMed ID: 28709696
    [No Abstract]   [Full Text] [Related]  

  • 50. Corrigendum to: ``The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target.'' J Bone Oncol. 2020 Feb; 20: 100271.
    Richert I; Gomez-Brouchet A; Bouvier C; Du Bouexic De Pinieux G; KaranianM A; Blay JY; Dutour A
    J Bone Oncol; 2020 Jun; 22():100287. PubMed ID: 32274326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Local recurrence after radical prostatectomy and salvage radiotherapy].
    Ojea Calvo A; Pérez Rodríguez A; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A; Otero García M; Muñoz Garzón V
    Arch Esp Urol; 2005; 58(1):17-23. PubMed ID: 15801646
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic options in patients with biochemical recurrence after radical prostatectomy.
    Bratu OG; Diaconu CC; Mischianu DLD; Constantin T; Stanescu AMA; Bungau SG; Ionita-Radu F; Marcu RD
    Exp Ther Med; 2019 Dec; 18(6):5021-5025. PubMed ID: 31798723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer.
    Aizawa R; Takayama K; Nakamura K; Inoue T; Kobayashi T; Akamatsu S; Yamasaki T; Ogawa O; Mizowaki T
    Int J Clin Oncol; 2018 Aug; 23(4):749-756. PubMed ID: 29556917
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prostate cancer recurrence after radical prostatectomy and salvage radiotherapy].
    Ojea Calvo A; Pérez Rodríguez A; Domínguez Freire F; Alonso Rodrigo A; Rodríguez Iglesias B; Benavente Delgado J; Barros Rodríguez JM; González Piñeiro A; Otero García M; Muñoz Garzón V
    Actas Urol Esp; 2004; 28(10):743-8. PubMed ID: 15666516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Corrigendum to 'Health-Promoting Lifestyle in Colorectal Cancer Survivors: A Qualitative Study on the Experiences and Perspectives of Colorectal Cancer Survivors and Healthcare Providers' [Asia-Pacific J Oncol Nursing 8 (2021) 696-710].
    Ramezanzade Tabriz E; Ramezani M; Heydari A; Aledavood SA
    Asia Pac J Oncol Nurs; 2022 Aug; 9(8):100106. PubMed ID: 35983241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Corrigendum to "A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger" [Radiother. Oncol. 132 (2019) 230-235].
    Shibuya K; Ohno T; Katoh H; Okamoto M; Shiba S; Koyama Y; Kakizaki S; Shirabe K; Nakano T
    Radiother Oncol; 2020 Feb; 143():126-127. PubMed ID: 32008869
    [No Abstract]   [Full Text] [Related]  

  • 57. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An international review of patient safety measures in radiotherapy practice: Shafiq J, Barton M, Noble D, Lemer C, Donaldson LJ. Radiother Oncol. 2009 Jul;92(1):15-21.
    Clark BG; Grimard L
    Radiother Oncol; 2009 Dec; 93(3):657. PubMed ID: 19767116
    [No Abstract]   [Full Text] [Related]  

  • 59. Corrigendum to "Commissioning and clinical implementation of an Autoencoder based Classification-Regression model for VMAT patient-specific QA in a multi-institution scenario" [Radiother. Oncol. 161 (2021) 230-240].
    Yang R; Yang X; Wang L; Li D; Guo Y; Li Y; Guan Y; Wu X; Xu S; Zhang S; Chan MF; Geng L; Sui J
    Radiother Oncol; 2021 Oct; 163():119-120. PubMed ID: 34488166
    [No Abstract]   [Full Text] [Related]  

  • 60. Corrigendum to "Successful radiological detection and surgical management of type 3 choledochocele: A case report" [Radiol Case Rep 2023;18:1502-6].
    Musleh A; Shrateh ON; Abbadi K; Asbah M; Sawalha N; Jobran AWM; Khader A
    Radiol Case Rep; 2023 May; 18(5):2061. PubMed ID: 37069952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.